Journal of Vascular Nursing
Volume 26, Issue 4 , Page 100 , December 2008

New clinical perspectives from nurses on aprotinin and fibrin sealants

References 

  1. Evans LA, Morey AF. Current applications of fibrin sealant in urologic surgery. Int Braz J Urol. 2006;32:131–141
  2. Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med. 2006;354:353–365
  3. FDA alert—BART: early communication about an ongoing safety review. Aprotinin injection (marketed as Trasylol). Available at: http://www.fda.gov/cder/drug/early_comm/aprotinin.htm. Accessed March 4, 2008.
  4. Mangano T, Miao Y, Vuylsteke A. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA. 2007;297:471–479
  5. Scheule A, Beierlein W, Wendel HP. Aprotinin in fibrin tissue adhesives induces specific antibody response in high-dose intravenous applications. J Thorac Cardiovasc Surg. 1999;118:348–353
  6. Beierlein W, Scheule A, Dietrich W, Ziemer G. Forty years of clinical aprotinin use: A review of 124 hypersensitivity reactions. Ann Thorac Surg. 2005;79:741–748

PII: S1062-0303(08)00113-1

doi: 10.1016/j.jvn.2008.09.002

Journal of Vascular Nursing
Volume 26, Issue 4 , Page 100 , December 2008

Article Tools